BioStock: Elicera Therapeutics strengthens financial standing in Q2

During Q2, Elicera was awarded a major grant from the European Innovation Council Accelerator Programme for its lead CAR T-cell project ELC-301 and concluded preclinical proof-of-concept studies with oncolytic virus project ELC-201. Financial developments during the quarter now mean that Elicera can fully finance its clinical programme until the first half of 2024. The Swedish gene therapy company is now looking forward to key development milestones in its pursuit to bring new cancer treatments to market. BioStock got in touch with CEO Jamal El-Mosleh for a comment.

Read the interview with Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2022/08/elicera-therapeutics-starkte-den-finansiella-stallningen-under-q2/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/